FDA rejects Capricor Therapeutics' cell therapy for Duchenne muscular dystrophy
The FDA has rejected a cell therapy developed by Capricor Therapeutics for patients with Duchenne muscular dystrophy, STAT reports. STAT How should regulators weigh hope in rare…
3 posts ·